

Investor Fact Sheet

March 2025



Company Overview

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Edwards has been advancing therapies to treat patients suffering from structural heart disease for more than 60 years, and this large and growing area is the company's specialty. Headquartered in Irvine, Calif., Edwards' life-saving innovations treat advanced cardiovascular disease and are sold in more than 100 countries. Edwards has manufacturing operations in North America, Europe, Singapore and Costa Rica.

Unique Innovation Strategy

Focusing on structural heart disease

Solving large and complex patient needs

Pioneering therapeutic categories

Poised for Long-Term Success

- Unwavering patient-focused culture motivates and guides our global team
- Credibility and trust with clinicians, regulators, payors and patients
- Transforming patient care drives growth and secures bright future

Quick Facts

Global Headquarters	Irvine, CA, USA
Worldwide Employees	~16,000
Website	edwards.com

Stock Information (as of March 31, 2025)

Stock Symbol	EW
Stock Exchange	NYSE
Stock Price	\$72.48
Shares Outstanding	587.8M
Market Capitalization	\$42.6B
Total Employee Ownership	Approximately 4%

Major Product Lines

Transcatheter Aortic Valve Replacement

In partnership with physicians worldwide, Edwards continues to lead the development of minimally invasive heart valve technologies enabling a streamlined procedure with excellent outcomes, rapid discharge and improved quality of life for patients with severe aortic stenosis. Through significant investment in technology advancement and clinical evidence, Edwards strives to further expand the treatment options for patients with severe aortic stenosis.



Transcatheter Mitral and Tricuspid Therapies



Edwards is making significant investments in the development of a differentiated portfolio of repair and replacement therapy options designed to treat mitral and tricuspid valve diseases.

Surgical

Edwards is committed to being the partner of choice for cardiac surgeons and relentlessly pioneering cardiac surgical innovation to improve the lives of patients globally. Edwards is the world's leading manufacturer of surgical tissue heart valve replacement and repair therapies.



Edwards

FINANCIAL PERFORMANCE

Non-GAAP Diluted Earnings Per Share




R&D Investment (in millions)



Q1 2025


Sales by Product Line



Percentages may not total due to rounding

Q1 2025

Sales by Geographic Location



Non-GAAP excludes certain unusual or infrequent charges


Financial performance figures are for continuing operations

INVESTOR RELATIONS CONTACT

(949) 250-2806
investor_relations@edwards.com
Main 1-800-4-A-HEART

Edwards' 5-Year Stock Performance as of March 31, 2025

EW: 15% S&P 500 Healthcare Equipment: 15% S&P 500: 117%



Product Innovations

Transcatheter Aortic Valve Replacement Edwards is the global leader in transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards [SAPIEN 3 Ultra](#), and the Edwards [SAPIEN 3 Ultra RESILIA](#) systems, are catheter-based approaches for treating patients who have severe symptomatic aortic stenosis. The proven SAPIEN family of valves is commercially available in over 75 countries and are the most widely implanted transcatheter heart valves in the world with over one million patients lives impacted since launch.

Edwards' most recently introduced SAPIEN 3 Ultra RESILIA system features RESILIA, an advanced class of tissue technology with unique anti-calcification properties, further elevating the performance of the SAPIEN 3 platform. This technology builds on Edwards' 40 years of leadership in tissue technology and durability. The SAPIEN 3 Ultra RESILIA system is also the only transcatheter heart valve to offer dry tissue storage. Additionally, the Edwards [SAPIEN 3](#) system and [Alterra](#) system offer a minimally invasive option for pulmonary valve replacement for patients with congenital heart disease.

The next generation SAPIEN X4 system is in development. Studies across our SAPIEN portfolio of TAVR devices in other patient populations are also continuing to enroll.

Transcatheter Mitral and Tricuspid Therapies Edwards remains focused on three key value drivers to unlock the significant long-term opportunity for patients: a portfolio of differentiated therapies; positive clinical trial results to support approvals and adoption; and favorable real-world clinical outcomes. Based on deep learnings the company has achieved from clinical trial and real-world experiences, Edwards has carefully constructed a strategic portfolio of leading transcatheter technologies to provide both repair and replacement solutions for Mitral and Tricuspid patients:

- [EVOQUE](#) transcatheter tricuspid replacement system is currently commercially available in the U.S. and Europe
- [PASCAL Precision](#) transcatheter valve repair system for mitral and tricuspid regurgitation received CE Mark in Europe, and FDA approval for Degenerative Mitral Regurgitation patients in the U.S. and is currently in clinical trials for Functional Mitral Regurgitation patients and Tricuspid repair
- SAPIEN M3 transfemoral transcatheter mitral replacement system is currently in clinical studies

Surgical Edwards is the global leader in surgical heart valve repair and tissue valve replacement with our RESILIA tissue valve innovations. The [MITRIS RESILIA](#) mitral valve is designed specifically for the higher pressures and anatomy of the mitral valve position. The [INSPIRIS RESILIA](#) aortic valve is the only valve with VFit technology to expand for potential future valve-in-valve procedures, and is the leading surgical aortic tissue valve globally. The [KONNECT RESILIA](#) aortic valved conduit is the first and only pre-assembled, tissue valved conduit designed for complex Bentall procedures where the aortic valve, root and ascending aorta are replaced.

CAUTION: The SAPIEN M3 System consists of investigational devices, limited by Federal (United States) law to investigational use. These devices are not available for marketing or commercial sale.

This document contains forward-looking statements that are based on estimates, assumptions and projections. Important factors that could cause results to differ materially from those expected by management may be found in documents filed by the company with the Securities and Exchange Commission. Some figures are not prepared in accordance with Generally Accepted Accounting Principles (GAAP). Visit edwards.com for a reconciliation of the differences between the GAAP and non-GAAP figures.

Edwards, Edwards Lifesciences, the stylized E logo, Alterra, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, Edwards SAPIEN 3 Ultra RESILIA, EVOQUE, INSPIRIS, INSPIRIS RESILIA, KONNECT, KONNECT RESILIA, MITRIS RESILIA, PASCAL, PASCAL Precision, RESILIA, SAPIEN, SAPIEN M3, SAPIEN X4, SAPIEN 3, SAPIEN 3 Ultra, SAPIEN 3 Ultra RESILIA, and VFit are trademarks of Edwards Lifesciences Corporation.

© 2025 Edwards Lifesciences. All rights reserved

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com



Edwards